Evidence map›Paper›PMID 33823077›Full record

ArticleThe oncologist2021

Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer.

Laila A Gharzai, Nicholas Burger, Pin Li, Elizabeth M Jaworski, Caitlin Henderson, Matthew Spector, Andy Rosko, Michelle M Chen, Mark E Prince, Carol R Bradford and 12 more

Abstract read
In one paragraph

Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Post-therapeutic surveillance of HPV-driven oropharyngeal cancers: are we ready to change our practices?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Trial
  2. Article
  3. A cross-sectional survey assessing clinicians' perspectives towards redesigning the surveillance model for head and neck cancer: can we do better?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  4. Article
  5. Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Laila A GharzaiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-6420-9274
Nicholas BurgerDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Pin LiDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Elizabeth M JaworskiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Caitlin HendersonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Matthew SpectorDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Andy RoskoDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Michelle M ChenDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Mark E PrinceDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Carol R BradfordDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Kelly M MalloyDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Chaz L StuckenDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Paul SwiecickiDepartment of Medical Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Francis WordenDepartment of Medical Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Matthew J SchipperDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Caitlin A SchonewolfDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Jennifer ShahDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Reshma JagsiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Steve ChinnDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Andrew ShumanDepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Keith Casper *Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Michelle L Mierzwa *Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
NCATS NIH HHS UL1 TR002240
6 · The paper itself

Abstract

introductionOptimal surveillance paradigms for survivors of early stage human papillomavirus (HPV)-related oropharyngeal cancer are not well defined. This study aimed to characterize patient interest in and factors associated with an altered surveillance paradigm. MATERIALS AND

methodsWe surveyed patients with Stage I or II HPV-related oropharyngeal cancer treated at a tertiary care institution from 2016 to 2019. Primary outcomes were descriptive assessment of patient knowledge, interest in altered surveillance, burdens of in-person appointments, and priorities for surveillance visits. Ordinal regression was used to identify correlates of interest in altered surveillance.

resultsSixty-seven patients completed surveys from February to April 2020 at a median of 21 months since completing definitive treatment. A majority (61%) of patients were interested in a surveillance approach that decreased in-person clinic visits. Patients who self-identified as medical maximizers, had higher worry of cancer recurrence, or were in long-term relationships were less likely to be interested. Patients reported significant burdens associated with surveillance visits, including driving distance, time off work, and nonmedical costs. Patients were most concerned with discussing cancer recurrence (76%), physical quality of life (70%), mortality (61%), and mental quality of life (52%) with their providers at follow-up visits.

conclusionPatients with early stage HPV-related oropharyngeal cancers are interested in altered surveillance approaches, experience significant burdens related to surveillance visits, and have concerns that are not well addressed with current surveillance approaches, including physical and mental quality of life. Optimized surveillance approaches should incorporate patient priorities and minimize associated burdens. IMPLICATIONS FOR PRACTICE: The number of patients with HPV-related oropharyngeal cancers is increasing, and numerous clinical trials are investigating novel approaches to treating these good-prognosis patients. There has been limited work assessing optimal surveillance paradigms in these patients. Patients experience significant appointment-related burdens and have concerns such as physical and mental quality of life. Additionally, patients with early stage HPV-related oropharyngeal cancers express interest in altered surveillance approaches that decrease in-person clinic visits. Optimization of surveillance paradigms to promote broader survivorship care in clinical practice is needed.

Indexed as

AlphapapillomavirusOropharyngeal NeoplasmsPapillomavirus InfectionsHumansNeoplasm Recurrence, LocalPapillomaviridaeQuality of LifeHuman papillomavirusOropharyngeal cancerSurveillanceSurvivorship

Identifiers

PMID33823077
PMCPMC8342565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.